The “Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)” Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum
Jonathan W. Rick(University of Arkansas for Medical Sciences), Alex G. Ortega‐Loayza(Oregon Health & Science University), Kim S Thomas(University of Nottingham), Marcia Friedman(Oregon Health & Science University), Diana Chen(Johnson Electric (China)), Amit Garg(Northwell Health), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Debbie L Oakes(South Shore Hospital), Toshiyuki Yamamoto(Fukushima Medical University), Afsáneh Alavi(Mayo Clinic in Arizona), Hans Herfarth(University of North Carolina at Chapel Hill), Angelo Valerio Marzano(University of Milan), Lisa J. Gould(Kent Hospital), Joachim Dissemond(Essen University Hospital)
Cited by 8
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity
|British Journal of Dermatology|2017|467
Animal Model of Sclerotic Skin. I: Local Injections of Bleomycin Induce Sclerotic Skin Mimicking Scleroderma
|Journal of Investigative Dermatology|1999|437
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419
Chronic wounds: Treatment consensus
|Wound Repair and Regeneration|2022|389